In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 28 for your search:
Drug:  vatalanib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPTK787 0135/306241, CONFIRM 1, NCT00056459
2.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Other
Protocol IDs: 2004-0248, NCT00088231
3.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 69
Sponsor: Other
Protocol IDs: EORTC-26041-22041, EORTC-26041, EORTC-22041, EUDRACT-2004-003896-35, NCT00128700
4.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: PANC0002, 95533, CPTK787AUS08, NCT00185588
5.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPTK787 0134/306220, NCT00171587
6.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DUMC-6626-04-12R0, NCT00303732
7.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000456195, UCSF-04557, NCT00293371
8.

Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UKSH A-105, EudraCT No. 2005-002192-32, NCT00615160
9.

Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000269537, U10CA031946, CALGB-30107, NCT00053885
10.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000339810, U10CA031946, CALGB-10105, NCT00072475
11.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2005.014, NCT00134355
12.

Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: 03-257, NCT00165347
13.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 91411, 2004-002290-22, 308801, NCT00160043
14.

Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: PCRT04-001, NCT00226005
15.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-0639, IND#: 72,721, NCT00240162
16.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-0970, NCT00263198
17.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787 A2401/300267, GIST PTK787/ZK222584, NCT00117299
18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 05C4, STU00005338, NU-1398-025, NOVARTIS-NU-05C4, NCT00348790
19.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CRCA-CCTC-CAMEL02, EU-20787, EUDRACT-2005-004710-33, CCTC-Camel-02, CCLG-Camel-02, ISRCTN191981, NCT00563823
20.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787/ZK222584, NCT00627198
21.

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: AMC-016, NOVARTIS-CPTK7870104
22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000386239, P30CA016042, UCLA-0403067-01, NOVARTIS-CPTK7870113, NCT00091299
23.

Phase: Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: 05-020, NCT00268918
24.

Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: DUMC-7019-06-3R1, NOVARTIS-DUMC-7019-06-3R1, NCT00387933
25.

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-046, NCT00358163
1   
New Search